Journal
TRENDS IN BIOTECHNOLOGY
Volume 33, Issue 2, Pages 132-140Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2014.12.001
Keywords
gene editing; gene targeting; homologous recombination; nonhomologous end-joining; ZFNs; TALENs; CRISPR/Cas9; RNA-guided endonucleases
Categories
Funding
- National Institutes of Health as a Nanomedicine Development Center Award [PN2EY018244]
- Myotonic Dystrophy Foundation
- Stanford School of Medicine
- National Science Foundation Graduate Research Fellowship [DGE-1148903]
- Laurie Kraus Lacob Faculty Scholar in Pediatric Translational Research
Ask authors/readers for more resources
Genome editing with engineered nucleases is a rapidly growing field thanks to transformative technologies that allow researchers to precisely alter genomes for numerous applications including basic research, biotechnology, and human gene therapy. While the ability to make precise and controlled changes at specified sites throughout the genome has grown tremendously in recent years, we still lack a comprehensive and standardized battery of assays for measuring the different genome editing outcomes created at endogenous genomic loci. Here we review the existing assays for quantifying on- and off-target genome editing and describe their utility in advancing the technology. We also highlight unmet assay needs for quantifying on- and off-target genome editing outcomes and discuss their importance for the genome editing field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available